Endpoints NewsOriginal article
AstraZeneca’s next-gen SERD Etcamah disappoints in untreated advanced breast cancer
Phase 3negativeEtcamahNegative
AI Analysis
Summary
AstraZeneca's Etcamah, a recently approved breast cancer drug, failed a Phase 3 trial designed to support label expansion into untreated advanced breast cancer, disappointing expectations for broader indication.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Failed late-stage trial for label expansion into untreated advanced breast cancer setting
Importance:7/10
Sentiment:
-0.80
breast cancerSERDlabel expansiontrial failureoncology
Related Companies
Read the original article
Published by Endpoints News on September 14, 2026 11:21 AM